MSc Cancer Immunotherapy with Placement Year

Master

In Hatfield

£ 12,400 VAT inc.

Description

  • Type

    Master

  • Location

    Hatfield

  • Duration

    2 Years

  • Start date

    Different dates available

Why choose Herts?
Teaching Excellence: You will be taught by Internationally renowned researchers who support with research projects in Cancer Immunotherapy.
Employment Prospects: Graduates work as research scientists, scientific officers, and senior managers for organisations including Roche, Merck, and Astra Zeneca.
Sector-led Course Content: Explore our research interests of the Bioscience Research Group covering topics such as Adoptive T cell therapy, tumour-associated macrophages, NK cells, and monoclonal antibodies in cancer therapy.

Facilities

Location

Start date

Hatfield (Hertfordshire)
See map
De Havilland Campus, Mosquito Way

Start date

Different dates availableEnrolment now open

About this course

The use of the immune system in cancer therapy is a prevailing ambition in the field. You’ll gain expert knowledge of the numerous ways cancers and the immune system interact so you can learn how cancer immunotherapies are developed. We’ll provide a thorough understanding of immune effector mechanisms and cancer biology. You’ll develop a range of personal skills through self-directed learning and our problem-based approach to teaching.

Alternatively, consider taking our other MSc Cancer Immunotherapy routes:

MSc Cancer Immunotherapy
MSc Cancer Immunotherapy with Advanced Research

You could make a valuable contribution to the ambitious work of cancer immunologists and play a key role in the activation of immune effector mechanisms for cancer therapy. Your skills and knowledge will be sought after in a range of careers in the immunotherapy industries. For example, Roche, Merck, Astra Zeneca and small to medium-sized enterprises. You could work in medical or pharmaceutical research and development, clinical trials, public health and epidemiology, academia research, medical writing and science journalism, education, or patent law. Alternatively, you may use your MSc Cancer Immunotherapy with Advanced Research to underpin an application to study for a research degree such as MRes, MSc by Research, or a PhD in a related field.

The normal entry requirements for the programme are:

65% or above average grade in an undergraduate degree in the Biological Sciences or
A professional qualification accepted as equivalent to the above; or
A qualification in veterinary science, medicine or dentistry; or
A first or second class Honours Degree in disciplines other than those described above but where the applicant, in the opinion of the Programme Leader, would benefit from, and succeed on, the programme.
Students will be selected through interview

Why choose this course?
You’ll be taught by our expert staff and innovative speakers from the biopharmaceutical industry.
Our modern Science Building provides excellent facilities for laboratory experiments, including DNA and genomic analysis eg QPCR, protein and proteomic science (eg MALDI-ToF), cell culture and Enzyme-based assays, isolated tissue studies and immunohistochemistry
When you graduate, you’ll be equipped to work in a broad range of fields including medical or pharmaceutical research and development, clinical trials, public health and epidemiology, academia research, medical writing and science journalism, education, or patent law
We adopt a blended learning approach to teaching, focussing on problem-based scenarios so you can develop strong critical analysis skills. You’ll benefit from exposure to practical techniques and guaranteed laboratory-based research projects
If successful you will have the opportunity to apply for a 12-month placement. If you are not successful in finding placement position then you can transfer to MSc Cancer Immunotherapy Advanced Research route.

Questions & Answers

Add your question

Our advisors and other users will be able to reply to you

Who would you like to address this question to?

Fill in your details to get a reply

We will only publish your name and question

Reviews

This centre's achievements

2020

All courses are up to date

The average rating is higher than 3.7

More than 50 reviews in the last 12 months

This centre has featured on Emagister for 6 years

Subjects

  • Teaching
  • Bioscience
  • Research
  • Bioscience Research
  • Microenvironment
  • Communication
  • Immune cells
  • Mechanisms
  • Communicate
  • Vaccines
  • Microbial

Course programme

What will I study?

You’ll benefit from the research interests of the Bioscience Research Group. These include studies of the tumour microenvironment and communication with infiltrating immune cells, the methods tumours employ to diminish the effectivity of immune effector mechanisms and how tumours communicate using extracellular vesicles with pre-metastatic sites. We’ll cover topics such as adoptive T cell therapy, tumour-associated macrophages, NK cells, monoclonal antibodies in cancer therapy, vaccines, microbial cancer therapies and immune checkpoint blockade.

Teaching will be delivered through lectures, tutorials and practical classes. You’ll immerse yourself in a research project which utilises problem-based and self-directed learning. You’ll explore case studies to gain a strong critical understanding. Through your research projects, carried out in our innovative Science Building and supervised by world-leading researchers, you’ll be trained in data collection, analysis and its interpretation. You’ll also benefit from expert external speakers from the biopharmaceutical industry.

Level 7

Module
  • Translational Medical Science
  • Contemporary Topics in Cancer Immunotherapy
  • Molecular Medicine
  • Molecular Cell Biology and Immunology

Additional information

Fees 2021

UK Students

Full time
£12400 for 2021/2022 and 2022/2023 inclusive

EU Students

Full time
£16650 for 2021/2022 and 2022/2023 inclusive

International Students

Full time
£16650 for 2021/2022 and 2022/2023 inclusive

MSc Cancer Immunotherapy with Placement Year

£ 12,400 VAT inc.